Impact of Age-Adjusted Charlson Comorbidity score on outcomes for patients with early-stage endometrial cancer

Is Older Age a Real Adverse Prognostic Factor in Women With Early-Stage Endometrial Carcinoma? A Matched Analysis

“…Worse OS in old women with endometrial carcinoma could be explained by increased prevalence of comorbidity such as diabetes mellitus, hypertension, coronary artery disease, and pulmonary dysfunction with old age. 8,14,18,25 In contrast to our study findings, several studies exist that suggest that older age is predictive of poorer outcomes. 12Y16 The results of these studies are difficult to interpret because of the lack of strategy to reduce confounding bias from other wellknown prognostic factors such as deep myometrial invasion, higher grade, and presence of LVSI.…”

Recurrence patterns and survival endpoints in women with stage II uterine endometrioid carcinoma: A multi-institution study

“…Additionally, patients were treated at different academic institutions with different philosophies in surgical and adjuvant treatment approaches. Furthermore, data on the depth of cervical stromal invasion [30], medical comorbidity [31,32] and treatment-related side effects were not available from all participated institutions.…”

What Is the Optimal Adjuvant Treatment Sequence for Node-Positive Endometrial Cancer? Results of a National Cancer Database Analysis

“…Comorbidity scores such as the age-adjusted Charlson Comorbidity Index have been shown to be as important as pathologic high-risk features for predicting OS. 8 Unfortunately, the modified Charlson Comorbidity Score used in NCDB is abbreviated and less granular as scores are coded as 0, 1, or greater than 2, in contrast to the original score, which can reach up to 15 points. While 5-year OS was better in women who received sequential versus concurrent treatment, there was a convergence of survival at longer follow-up times, which makes interpretation difficult.…”